Literature DB >> 30123545

cT2N0 esophageal cancer remains a difficult diagnosis.

Jon O Wee1.   

Abstract

Entities:  

Year:  2018        PMID： 30123545      PMCID： PMC6072960          DOI： 10.21037/jtd.2018.06.31

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  6 in total

1.  Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer.

Authors:  Paul J Speicher; Asvin M Ganapathi; Brian R Englum; Matthew G Hartwig; Mark W Onaitis; Thomas A D'Amico; Mark F Berry
Journal:  J Thorac Oncol       Date:  2014-08       Impact factor: 15.609

Review 2.  Neoadjuvant therapy or upfront surgery? A systematic review and meta-analysis of T2N0 esophageal cancer treatment options.

Authors:  F C Mota; I Cecconello; F R Takeda; F Tustumi; R A A Sallum; W M Bernardo
Journal:  Int J Surg       Date:  2018-05-03       Impact factor: 6.071

3.  Comparative effectiveness of upfront esophagectomy versus induction chemoradiation in clinical stage T2N0 esophageal cancer: A decision analysis.

Authors:  Tara R Semenkovich; Roheena Z Panni; Jessica L Hudson; Theodore Thomas; Leisha C Elmore; Su-Hsin Chang; Bryan F Meyers; Benjamin D Kozower; Varun Puri
Journal:  J Thorac Cardiovasc Surg       Date:  2018-01-12       Impact factor: 5.209

4.  Clinical T2N0 Esophageal Cancer: Identifying Pretreatment Characteristics Associated With Pathologic Upstaging and the Potential Role for Induction Therapy.

Authors:  Pamela Samson; Varun Puri; Clifford Robinson; Craig Lockhart; Danielle Carpenter; Stephen Broderick; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Bryan Meyers; Traves Crabtree
Journal:  Ann Thorac Surg       Date:  2016-04-12       Impact factor: 4.330

5.  Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer.

Authors:  Manfred P Lutz; John R Zalcberg; Michel Ducreux; Jaffer A Ajani; William Allum; Daniela Aust; Yung-Jue Bang; Stefano Cascinu; Arnulf Hölscher; Janusz Jankowski; Edwin P M Jansen; Ralf Kisslich; Florian Lordick; Christophe Mariette; Markus Moehler; Tsuneo Oyama; Arnaud Roth; Josef Rueschoff; Thomas Ruhstaller; Raquel Seruca; Michael Stahl; Florian Sterzing; Eric van Cutsem; Ate van der Gaast; Jan van Lanschot; Marc Ychou; Florian Otto
Journal:  Eur J Cancer       Date:  2012-08-23       Impact factor: 9.162

6.  Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study.

Authors:  Sheraz R Markar; Caroline Gronnier; Arnaud Pasquer; Alain Duhamel; Hélène Beal; Jérémie Théreaux; Johan Gagnière; Gil Lebreton; Cécile Brigand; Bernard Meunier; Denis Collet; Christophe Mariette
Journal:  Eur J Cancer       Date:  2016-01-23       Impact factor: 9.162
  6 in total
  1 in total

1.  The role of a decision analysis in treatment of T2N0 esophageal cancer.

Authors:  Tara R Semenkovich; Bryan F Meyers; Benjamin D Kozower; Varun Puri
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.